Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells

Cancer Research

Volumn 77, Issue 19, 2017, Pages 5384-5394

  Chang, Chien Hsing ^a,b   Wang, Yang ^a   Li, Rongxiu ^a   Rossi, Diane L ^a   Liu, Donglin ^a,b   Rossi, Edmund A ^a   Cardillo, Thomas M ^a   Goldenberg, David M ^a,b  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; TROP 2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; CARCINOEMBRYONIC ANTIGEN; CEACAM5 PROTEIN, HUMAN; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PDCD1 PROTEIN, HUMAN; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IC50; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CYTOTOXICITY; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; T LYMPHOCYTE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MICE, SCID; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85031502487     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-3431     Document Type: Article

References (50)

1. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancers. Science 2015;348:62–8.
2. Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech 2015;8:337–50.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61.
4. Del Bano J, Chames P, Baty D, Kerfelec B. Taking up cancer immunotherapy challenges: bispecific antibodies, the path forward? Antibodies 2016;5:1–23.
5. Carlino MS, Long GV. Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma? Clin Cancer Res 2016;22:3992–8.
6. Sakuishi K, Apeto L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187–94.
7. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2011; 72:917–27.
8. Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res 2015;3:149–60.
9. Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 2013;11:215.
10. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 2014;12:36.
11. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636–46.
12. Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 2014;74:5561–71.
13. Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J 2015;5:e340.
14. Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in number. J Leukoc Biol 2016;100:275–90.
15. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol 2015;8:130.
16. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015;20:838–47.
17. Spiess C, Zhai Q, Carter PJ. Alternative formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67:95–106.
18. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Quaret D, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res 2016;22:3286–97.
19. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435–43.
20. Moore GL, Bautista C, Pong E, Nguyen D-H T, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs 2011;3: 546–57.
21. Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs 2014;6:381–91.
22. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005;10:1237–44.
23. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004;279:53907–14.
24. Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, et al. Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 2010;285:20844–9.
25. McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 2012;8:687–95.
26. Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, et al. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res 2016;22:5829–38.
27. Rozan C, Comillon A, Petiard C, Chartier M, Behar G, Boix C, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting FcgRIII induces potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther 2013;12:1481–91.
28. Rossi EA, Rossi DL, Cardillo TM, Chang CH, Goldenberg DM. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispepcifc antibody is enhanced in combination with interferon-a. Mol Cancer Ther 2014;13:2341–51.
29. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009; 4:309–24.
30. Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers. Mol Cancer Ther 2016;15:1910–9.
31. Rossi DL, Rossi EA, Goldenberg DM, Chang CH. A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines. Biotechnol Prog 2011;27:766–75.
32. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864–71.
33. Brockhoff G, Hofstaedter F, Knuechel R. Flow Cytometric Detection and quantitation of the epidermal growth factor receptor in comparison to scatchard analysis in human bladder carcinoma cell lines. Cytometry 1994;17:75–83.
34. Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014;6:1571–84.
35. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361–70.
36. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother 2010;59:1675–84.
37. Sapra P, Darmelin M, DiJoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013;12:38–47.
38. Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A, et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocytes infiltration. Int J Cancer 2009;124:2589–96.
39. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, et al. Bispecific antibodies with natural architecture produced by co-culture of bacterial expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753–8.
40. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs 2016;8:1010–20.
41. Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, et al. In vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals highly specific tumor targeting and fast induction of T-cell–mediated tumor killing. Clin Cancer Res 2016;22:4417–27.
42. Blumenthal RD, Hansen HJ, Goldenberg DM. In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies. Br J Cancer 2008;99:837–8.
43. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010;59:1197–1209.
44. Durbin H, Young S, Stewart LM, Wrba F, Rowan AJ, Snary D, et al. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci U S A 1994;91:4313–7.
45. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–18.
46. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. ChimericantigenreceptorTcellspersistandinducesustainedremissionsin relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7:303ra139.
47. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209–21.
48. Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA Approval: Blinatumomab. Clin Cancer Res 2015;21:4035–9.
49. Wu CY, Rupp LJ, Roybal KT, Lim WA. Synthetic biology approaches to engineer T cells. Curr Opin Immunol 2015;35:123–30.
50. Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, et al. Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 2016;3:506–17.